Venus Remedies share price
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,404.30down ₹37.20 (2.58%)BSE ₹1,396.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,441.50.
52-week range of traded prices to 23 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,877 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 Jul 2026
- 16.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 2.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 Jul 2026
- 19.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 Jul 2026
- 21.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day.
- 52,800
Results
Standalone, as consolidated accounts are on record for only 9 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 20 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹179 Crdown 30.97%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹26 Crdown 41.27%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 14.3%
Revenue by year
Peak revenue ₹769 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 3 of the 10 years shown
| ₹ crore | Sep 2024Filed 29 Oct | Dec 2024Filed 4 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 10 Nov | Sep 2025Filed 10 Nov | Dec 2025Filed 29 Jan | Mar 2026Filed 26 May | Jun 2026Filed 20 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 167 | 173 | 194 | 137 | 193 | 180 | 259 | 179 |
| Net profit | 9 | 24 | 15 | 12 | 19 | 25 | 43 | 26 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 5.5% | 14.0% | 7.6% | 8.5% | 10.0% | 13.8% | 16.8% | 14.3% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 57% of 1,774 trading days over the last 10 years.
LowestHighest
Its median15.4Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 95% of 1,819 trading days since Nov 2018.
LowestHighest
Its median0.8Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.11.1
At or below today's level on 93% of 1,819 trading days since Nov 2018.
LowestHighest
Its median7.1Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 100% of 2,473 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.51%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +175.1% | +88.9% | +44.9% | 1.2% |
| 3 years | +71.9% | +50.8% | +13.8% | 0.4% |
| 5 years | +24.7% | +11.1% | +12.0% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 1 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2021 and Mar 2025.
Mutual funds holding it
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 212 | 0.09% | ₹0.04 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 100 | 0.09% | ₹0.02 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Venus Remedies in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sai ParenteralsSAIPARENT | 2,040 | – | 4.2 | – | – | – | – | – | 0.00% |
 Syncom Formulations (India)SYNCOMF | 1,992 | 23.3 | 4.8 | 22.6 | +0.4% | +48.6% | 22.6% | 19.5% | 0.47% |
 Sakar HealthcareSAKAR | 1,980 | 46.2 | 5.7 | 22.4 | +48.0% | +119.8% | 13.2% | 16.6% | 0.00% |
 Panacea BiotecPANACEABIO | 1,908 | – | 2.3 | 852.5 | +10.3% | −162.0% | −0.9% | −3.6% | 0.00% |
 Windlas BiotechWINDLAS | 1,801 | 27.1 | 3.1 | 17.4 | +18.5% | +2.4% | 12.2% | 12.2% | 0.72% |
 Hester BiosciencesHESTERBIO | 1,750 | 12.8 | 4.9 | 22.3 | +4.1% | +262.2% | 40.4% | 11.7% | 0.53% |
 NGL Fine-ChemNGLFINE | 1,634 | 28.6 | 5.0 | 20.6 | +40.5% | – | 18.7% | 14.5% | 0.07% |
 Amrutanjan Health CareAMRUTANJAN | 1,410 | 26.1 | 3.8 | 18.7 | +10.7% | −1.0% | 15.5% | 18.0% | 1.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹10.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 7 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹10.00 |
| 23 Sep 2013 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 20 Sep 2012 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 22 Sep 2011 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 23 Sep 2010 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 17 Sep 2009 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Aug 2026
Venus Remedies share price by year
Each calendar year to 2025.Venus Remedies share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 766.10 | +140.6% | 833.40 | 275.90 |
| 2024 | 318.45 | −21.6% | 420.95 | 287.55 |
| 2023 | 406.25 | +124.3% | 413.40 | 147.75 |
| 2022 | 181.10 | −55.7% | 412.75 | 174.10 |
| 2021 | 408.80 | +172.3% | 611.45 | 157.55 |
| 2020 | 150.15 | +570.3% | 151.35 | 21.50 |
| 2019 | 22.40 | −48.2% | 44.40 | 20.00 |
| 2018 | 43.25 | −57.8% | 125.45 | 34.90 |
| 2017 | 102.50 | +6.2% | 114.65 | 88.25 |
| 2016 | 96.55 | −24.5% | 137.30 | 65.95 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,441.00 | 1,461.90 | 1,369.50 | 1,404.30 | 1,397.72 | 52,800 |
| 22 Oct 2026 | 1,513.60 | 1,525.00 | 1,438.20 | 1,441.50 | 1,458.39 | 74,318 |
| 21 Oct 2026 | 1,593.20 | 1,603.90 | 1,513.60 | 1,513.80 | 1,528.39 | 23,359 |
| 19 Oct 2026 | 1,650.00 | 1,650.00 | 1,581.20 | 1,593.20 | 1,604.98 | 18,658 |
| 16 Oct 2026 | 1,587.90 | 1,650.80 | 1,565.50 | 1,650.70 | 1,623.35 | 32,233 |
| 15 Oct 2026 | 1,587.00 | 1,594.00 | 1,551.10 | 1,572.20 | 1,574.22 | 25,245 |
| 14 Oct 2026 | 1,586.40 | 1,605.00 | 1,550.00 | 1,574.30 | 1,575.03 | 14,939 |
| 13 Oct 2026 | 1,605.00 | 1,627.30 | 1,561.10 | 1,585.50 | 1,581.82 | 18,764 |
| 12 Oct 2026 | 1,610.00 | 1,639.90 | 1,581.10 | 1,620.40 | 1,613.23 | 14,379 |
| 9 Oct 2026 | 1,636.60 | 1,665.90 | 1,597.00 | 1,610.10 | 1,613.64 | 39,011 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Venus Remedies Limited
- NSE symbol
- VENUSREM
- BSE code
- 526953
- ISIN
- INE411B01019
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 1995 on BSE, Dec 2006 on NSE
- Face value
- ₹10
- CIN
- L24232CH1989PLC009705
- Corporate identity number, the registrar of companies' code for it